Company Analysis Biohaven Pharmaceutical Holding Company Ltd.
1. Summary
Advantages
- Price (10.81 $) is less than fair price (18.01 $)
- Current debt level 5.95% is below 100% and has decreased over 5 years from 239.87%.
Disadvantages
- Dividends (0%) are below the sector average (1.36%).
- The stock's return over the last year (-42.1%) is lower than the sector average (-0.9479%).
- The company's current efficiency (ROE=-198.83%) is lower than the sector average (ROE=-74.13%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Biohaven Pharmaceutical Holding Company Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.4% | 0.7% | 0.2% |
| 90 days | -34.4% | 7.2% | 2.5% |
| 1 year | -42.1% | -0.9% | 16.6% |
BHVN vs Sector: Biohaven Pharmaceutical Holding Company Ltd. has significantly underperformed the "Healthcare" sector by -41.15% over the past year.
BHVN vs Market: Biohaven Pharmaceutical Holding Company Ltd. has significantly underperformed the market by -58.72% over the past year.
Stable price: BHVN is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BHVN with weekly volatility of -0.8096% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (10.81 $) is lower than the fair price (18.01 $).
Price significantly below the fair price: The current price (10.81 $) is 66.6% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-1.45) is lower than that of the sector as a whole (142.19).
P/E vs Market: The company's P/E (-1.45) is lower than that of the market as a whole (73.05).
5.3. P/BV
P/BV vs Sector: The company's P/BV (8.05) is lower than that of the sector as a whole (18.07).
P/BV vs Market: The company's P/BV (8.05) is lower than that of the market as a whole (20.45).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (13.12) is lower than that of the sector as a whole (14.7).
P/S vs Market: The company's P/S indicator (13.12) is lower than that of the market as a whole (30.65).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.97) is lower than that of the sector as a whole (61.62).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.97) is lower than that of the market as a whole (36.12).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 59.18% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (59.18%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-74.62%).
6.4. ROE
ROE vs Sector: The company's ROE (-198.83%) is lower than that of the sector as a whole (-74.13%).
ROE vs Market: The company's ROE (-198.83%) is lower than that of the market as a whole (51.58%).
6.6. ROA
ROA vs Sector: The company's ROA (-150.03%) is lower than that of the sector as a whole (6.62%).
ROA vs Market: The company's ROA (-150.03%) is lower than that of the market as a whole (11.19%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.38%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (45.09%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.36%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 05.01.2025 | Coric Vlad Chief Executive Officer |
Purchase | 39.51 | 563 018 | 14 250 |
| 05.01.2025 | Buten Matthew Chief Financial Officer |
Purchase | 39.51 | 167 918 | 4 250 |
| 05.01.2025 | Clark George C. VP, Chief Accounting Officer |
Purchase | 39.51 | 98 775 | 2 500 |
| 19.08.2022 | Bailey Gregory Director |
Purchase | 148.04 | 5 625 520 | 38 000 |
| 07.01.2022 | Coric Vlad Chief Executive Officer |
Purchase | 129.48 | 1 294 800 | 10 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
